Alpha Cognition Inc.
ACOG evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ACOG—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ACOG
Alpha Cognition Inc. is a biopharmaceutical company focused on developing and commercializing therapies for neurodegenerative diseases, with one FDA-approved product (ZUNVEYL) for Alzheimer's disease and a pipeline of earlier-stage candidates.
Key risk: No commercial track record
BioSniper Score
Based on 6 of 6 signals
Market Cap
$199.5M
Cash Runway
20.3 moLead Asset
alpha-1062 sublingual (Preclinical)
Next Catalyst
Patent_Expiry · Jul 23, 2045Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial · 1 catalyst · 1 FDA decision for Alpha Cognition Inc..
Alpha Cognition Inc. is a biopharmaceutical company focused on developing and commercializing therapies for neurodegenerative diseases, with one FDA-approved product (ZUNVEYL) for Alzheimer's disease and a pipeline of earlier-stage candidates.
- Alpha Cognition has one FDA-approved product, ZUNVEYL oral tablets, for Alzheimer's disease, but has not yet demonstrated commercial-scale manufacturing or sales capabilities [sec · filed 2024-10-16].
- As of June 30, 2026, the company reported cash & equivalents of $41.4M, total revenue of $6.1M, and a net loss of -$8.8M [sec].
- The company has a history of operating losses and negative cash flow from operations since inception, with an accumulated deficit of $78.3M as of March 31, 2025 [sec_mda · as of 2025-05-15].
- Management estimates existing cash will fund base operating expenses, initial ZUNVEYL commercialization costs, and planned CMC costs through at least the next 24 months as of the latest filing [sec_mda · as of 2026-08-13].
- The company's future depends on its ability to raise additional capital and generate revenue from ZUNVEYL or other product candidates [sec_mda · as of 2025-05-15].
What works
- Alpha Cognition has obtained FDA approval for ZUNVEYL, a product for Alzheimer's disease, representing a regulatory milestone and potential revenue source [sec · filed 2024-10-16].
- As of June 30, 2026, the company holds $41.4M in cash and equivalents, providing a runway to fund planned operations and initial commercialization activities for at least 24 months [sec_mda · as of 2026-08-13].
- The company has a pipeline of other product candidates beyond ZUNVEYL, offering potential diversification if development is successful [sec_mda · as of 2026-08-13].
What to weigh
- Alpha Cognition has no history of commercializing products and has not demonstrated the ability to manufacture, market, or sell ZUNVEYL at a commercial scale [sec · filed 2024-10-16].
- The company has incurred significant operating losses since inception, with an accumulated deficit of $78.3M as of March 31, 2025, and expects negative cash flow for the foreseeable future [sec_mda · as of 2025-05-15].
- The company's ability to continue as a going concern is dependent on obtaining additional funding and generating cash flows, which is uncertain [sec_mda · as of 2025-05-15].
- Revenue generation from ZUNVEYL is uncertain, as it relies on patients' willingness to pay out-of-pocket in the absence of adequate insurance coverage or reimbursement [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
The company has only one approved product and no commercial history.
“To date, we have successfully obtained regulatory approval for only one product, ZUNVEYL oral tablets, and have not demonstrated our ability to manufacture a product on a commercial scale, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization.”
SEC filings · October 16, 2024
The company has a history of losses and negative cash flow.
“The Company has reported negative cash flow from operating activities since inception and expects to experience negative operating cash flows for the foreseeable future.”
SEC MD&A · May 15, 2025
The company's future depends on raising additional capital.
“The Company's continuing operations, as intended, are highly dependent upon its ability to obtain additional funding and generate cash flows.”
SEC MD&A · May 15, 2025
Catalyst timeline
- 2045-07-23 · Patent_Expiry · ZUNVEYL — Patent or exclusivity expiry for ZUNVEYL, which could affect market exclusivity and competitive positioning.
Risks & what to watch (4)›
Key risks
- No commercial track record — Alpha Cognition has never commercialized a product and lacks experience in large-scale manufacturing, sales, and marketing [sec · filed 2024-10-16].
- Going concern uncertainty — The company has negative cash flow from operations since inception and must raise additional capital to continue operations [sec_mda · as of 2025-05-15].
- Reimbursement risk for ZUNVEYL — Revenue from ZUNVEYL depends on patients' willingness to pay out-of-pocket without adequate insurance coverage [sec_mda · as of 2026-08-13].
- Pipeline development risk — Other product candidates are in early stages and may fail to obtain regulatory approval or generate revenue [sec · filed 2024-12-31].
What to watch
- Commercial launch progress and initial sales of ZUNVEYL for Alzheimer's disease [sec_mda · as of 2026-08-13].
- Ability to secure additional financing to extend cash runway beyond the current 24-month estimate [sec_mda · as of 2026-08-13].
- Development updates on other product candidates beyond ZUNVEYL [sec_mda · as of 2026-08-13].
- Reimbursement decisions by third-party payors that could affect ZUNVEYL adoption [sec_mda · as of 2026-08-13].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Alpha Cognition Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Alpha Cognition Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
20.3 months
D/E 0.22 · 0% dilution
Lead: Preclinical
2 candidates
1 upcoming, next in ~6902d
41 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
20
Total value held
$10.6M
| Holder | Shares | Value |
|---|---|---|
| sphera funds management ltd. | 567,616 | $3.1M |
| alyeska investment group, l.p. | 365,000 | $2.0M |
| boothbay fund management, llc | 256,393 | $1.4M |
| aristides capital llc | 218,510 | $1.2M |
| cantor fitzgerald, l. p. | 188,631 | $1.0M |
| citadel advisors llc | 89,589 | $492K |
| villere st denis j & co llc | 71,158 | $391K |
| tudor investment corp et al | 61,596 | $338K |
| act capital management, llc | 51,500 | $283K |
| berkshire asset management llc/pa | 19,824 | $109K |
Showing top 10 of 20 institutional holders of Alpha Cognition Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 22, 2026- % of float
- 1.6%
- Days to cover
- 5.7
- Shares short
- 327,498
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ACOG short interestGovernance
Frequently asked questions
What is the AI investment thesis for Alpha Cognition Inc.?
Alpha Cognition Inc. is a biopharmaceutical company focused on developing and commercializing therapies for neurodegenerative diseases, with one FDA-approved product (ZUNVEYL) for Alzheimer's disease and a pipeline of earlier-stage candidates.
What is Alpha Cognition Inc.'s lead drug candidate?
Alpha Cognition Inc.'s most advanced tracked candidate is alpha-1062 sublingual (Preclinical) for cognitive impairment with mild traumatic brain injury (mTBI; otherwise known as concussion).
What is Alpha Cognition Inc.'s next catalyst?
Alpha Cognition Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ZUNVEYL" — expected July 23, 2045.
Who is the CEO of Alpha Cognition Inc.?
Mr. Michael E. McFadden B.B.A. is the chief executive officer of Alpha Cognition Inc. (ACOG).
Where is Alpha Cognition Inc. headquartered?
Alpha Cognition Inc. (ACOG) is headquartered in Grapevine, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.